| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Department of Surgical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands
Correspondence: Address correspondence and reprint requests to: A. M. M. Eggermont, MD, PhD; E-mail: a.m.m.eggermont{at}erasmusmc.nl.
Background: Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation. Tumor necrosis factor (TNF)-
based isolated limb perfusion (ILP) is an established alternative to achieve limb salvage but is assumed to require sufficient vasculature. Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.
Methods: We consulted a prospective database of TNF-based ILPs at the Erasmus MC–Daniel den Hoed Cancer Center in Rotterdam. Out of 342 TNF-based ILPs between 1991 and 2003, 30 ILPs were performed in 26 patients with recurrent STS in the irradiated field after prior surgery and radiotherapy. Eleven patients (42%) had multiple tumors (n = 2–20). All patients were candidates for amputation.
Results: We observed 6 complete responses (20%), 15 partial responses (50%), no change in 8 patients (27%), and progressive disease in 1 patient (3%). The median duration of response was 16 months (range, 3–56 months) at a median follow-up of 22 months (range, 3–67 months). The local recurrence rate was 45% in patients with multiple tumors and 27% in patients with single tumors. Ten patients (35%) died of systemic metastases. Limb salvage was achieved in 17 patients (65%). Regional toxicity was limited and systemic toxicity minimal.
Conclusions: TNF-based ILP can avoid amputations in most patients with recurrent extremity STS in a prior operated and irradiated field.
Key Words: Isolated limb perfusion • Soft tissue sarcoma • Limb salvage • TNF • Radiotherapy
This article has been cited by other articles:
 |
|
 |
|
  P. Hohenberger and W. M. Wysocki Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist, February 1, 2008; 13(2): 175 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Hoven-Gondrie, K. M. J. Thijssens, J. J. A. M. Van den Dungen, J. Loonstra, R. J. van Ginkel, and H. J. Hoekstra Long-Term Locoregional Vascular Morbidity After Isolated Limb Perfusion and External-Beam Radiotherapy for Soft Tissue Sarcoma of the Extremity Ann. Surg. Oncol., July 1, 2007; 14(7): 2105 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pennacchioli, M. Deraco, L. Mariani, M. Fiore, C. Mussi, P. Collini, P. Olmi, P. G. Casali, M. Santinami, and A. Gronchi Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution Ann. Surg. Oncol., February 1, 2007; 14(2): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. J. Thijssens, R. J. van Ginkel, E. Pras, A. J. H. Suurmeijer, and H. J. Hoekstra Isolated Limb Perfusion With Tumor Necrosis Factor {alpha} and Melphalan for Locally Advanced Soft Tissue Sarcoma: The Value of Adjuvant Radiotherapy Ann. Surg. Oncol., April 1, 2006; 13(4): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van Horssen, T. L. M. ten Hagen, and A. M. M. Eggermont TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Oncologist, April 1, 2006; 11(4): 397 - 408. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
